Alogliptin | SYR-322 free base;SYR 322 | 阿洛利停 | Diabete | DPP4

首页 / / / / Alogliptin

阿格列汀 /Alogliptin {[allProObj[0].p_purity_real_show]}

货号：A295732 同义名： 阿洛利停 / SYR-322 free base;SYR 322

Alogliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor with IC50 of 6.9 nM that exhibits greater selective than DPP-2, DPP-8 and DPP-9.

Alogliptin 化学结构
CAS号：850649-61-5

Alogliptin 3D分子结构
CAS号：850649-61-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Alogliptin 纯度/质量文件产品仅供科研

货号：A295732 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

Alogliptin 生物活性

描述

Dipeptidylpeptidase 4 (DPP4) belongs to the S9b gene family of postproline serine peptidases. It acts mostly as a secreted membrane protein, mediating the degradation and inactivation of glucagon-like peptide (GLP)-1 and gastric inhibitory protein (GIP). Alogliptin is a potent, selective inhibitor of the DPP-4 with IC_{50_{value of 2.63 nM in enzymatic assay. And it has nearly 1000-fold higher IC₅₀ for DPP8/9 inhibition than for DPP4 inhibition^[3]. In rats, dogs, and monkeys, the absolute oral bioavailability of alogliptin was 45%, 86%, and 72% to 88%, respectively. After a single oral dose of alogliptin, plasma DPP-4 inhibition was observed within 15 min and maximum inhibition was > 90% in rats, dogs, and monkeys; inhibition was sustained for 12 h in rats (43%) and dogs (65%) and 24 h in monkeys (> 80%). In Zucker fa/fa rats, a single dose of alogliptin (0.3, 1, 3, and 10 mg/kg) inhibited plasma DPP-4 (91% to 100% at 2 h and 20% to 66% at 24 h), increased plasma concentration of GLP-1 and early-phase insulin secretion and reduced blood glucose excursion after oral glucose challenge^[4].}}

Alogliptin 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03492580	-		Completed	-	United States, New Jersey ... 展开 >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 收起 <<
NCT02312427	Heart Failure ... 展开 >> Diabetes Mellitus 收起 <<	Phase 4	Completed	-	Japan ... 展开 >> Mitsui Memorial Hospital Taito-ku, Tokyo, Japan 收起 <<
NCT02528019	Effects of the DPP-4 Inhibitor... 展开 >>s or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications 收起 <<	Phase 4	Unknown	August 2018	Japan ... 展开 >> Kurume University Hospital Recruiting Kurume city, Japan, 830-0011 Contact: Nobuhiro Tahara, MD, PhD +81-942-31-7580 ntahara@med.kurume-u.ac.jp Contact: Sho-ichi Yamagishi, MD, PhD +81-942-31-7562 Principal Investigator: Nobuhiro Tahara, MD, PhD 收起 <<

Alogliptin 参考文献

[1]Moritoh Y, Takeuchi K, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54.

[2]Feng J, Zhang Z, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300.

[3]Huan Y, Jiang Q, Liu JL, Shen ZF. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:8-12. doi: 10.1016/j.vascn.2014.11.002. Epub 2014 Nov 15. PMID: 25464020.

[4]Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol. 2008 Jul 28;589(1-3):306-14. doi: 10.1016/j.ejphar.2008.04.047. Epub 2008 Apr 26. PMID: 18538760.

Alogliptin 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.95mL

0.59mL

0.29mL

14.73mL

2.95mL

1.47mL

29.46mL

5.89mL

2.95mL

Alogliptin 技术信息

CAS号	850649-61-5
分子式	C₁₈H₂₁N₅O₂
分子量	339.392

别名	阿洛利停 ;SYR-322 free base;SYR 322
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(309.38 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 10 mg/mL(29.46 mM)，配合低频超声，并水浴加热至45℃助溶

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03492580	-		Completed	-	United States, New Jersey ... 展开 >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 收起 <<
NCT02312427	Heart Failure ... 展开 >> Diabetes Mellitus 收起 <<	Phase 4	Completed	-	Japan ... 展开 >> Mitsui Memorial Hospital Taito-ku, Tokyo, Japan 收起 <<
NCT02528019	Effects of the DPP-4 Inhibitor... 展开 >>s or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications 收起 <<	Phase 4	Unknown	August 2018	Japan ... 展开 >> Kurume University Hospital Recruiting Kurume city, Japan, 830-0011 Contact: Nobuhiro Tahara, MD, PhD +81-942-31-7580 ntahara@med.kurume-u.ac.jp Contact: Sho-ichi Yamagishi, MD, PhD +81-942-31-7562 Principal Investigator: Nobuhiro Tahara, MD, PhD 收起 <<
NCT00751868	Breast Cancer	Phase 2	Completed	-	Italy ... 展开 >> Azienza Osped.Treviglio - Caravaggio Treviglio, BG, Italy, 24047 Azienda Ospedaliera G. Rummo Benevento, BN, Italy, 82100 Ospedale Civile di Campobasso - A. Cardarelli Campabasso, CB, Italy, 86100 Ospedale civile Renzetti di Lanciano Lanciano, CH, Italy, 66034 Azienda Ospedaliera S. Anna Como, CO, Italy, 22100 Azienda Ospedaliera Nesina Garibaldi Catania, CT, Italy, 95124 I.S.T. - Istituto Nazionale per la Ricerca sul Cancro Genova, GE, Italy, 16131 Presidio Ospedaliero di Macerata Mecerata, MC, Italy, 62100 I.R.C.C.S. Multimedica - Casa di Cura Accreditata Sesto San Giovanni, Milano, Italy, 20099 Azienda Ospedaliera R. Silvestrini Perugia, PG, Italy, 06132 Azienda Ospedaliera SS. Annunziata Sassari, SS, Italy, 07100 Ospedale S. Cuore Don Calabria Negrar, Verona, Italy, 37024 Ist. Nazionale per lo Studio e la Cura dei Tumori - Fondazione Pascale Napoli, Italy, 80131 Università Federico II Napoli, Italy, 80131 Istituto Regina Elena Roma, Italy, 00100 收起 <<
NCT01075763	-		Completed	-	-
NCT00763347	Diabetes Mellitus	Phase 2	Terminated(Voluntarily termina... 展开 >>ted based on preliminary non-clinical findings.) 收起 <<	-	-
NCT03014479	Type 2 Diabetes	Phase 4	Completed	-	Japan ... 展开 >> Nagoya, Aichi, Japan Kanra, Gunma, Japan Kobe, Hyogo, Japan Koga, Ibaraki, Japan Kawasaki, Kanagawa, Japan Sagamihara, Kanagawa, Japan Yamato, Kanagawa, Japan Sendai, Miyagi, Japan Kashihara, Nara, Japan Kashiwara, Osaka, Japan Suita, Osaka, Japan Okegawa, Saitama, Japan Oyama, Tochigi, Japan Adachi-ku, Tokyo, Japan Chuo-ku, Tokyo, Japan Edogawa-ku, Tokyo, Japan Musashino, Tokyo, Japan Oota-ku, Tokyo, Japan Shibuya-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Shinjyuku-ku, Tokyo, Japan Osaka, Japan 收起 <<
NCT01588587	-		Unknown	December 2017	Japan ... 展开 >> Kurume University Not yet recruiting Kurume, Fukuoka, Japan, 830-0111 Contact: Sho-ichi Yamagishi, MD +81-942-31-7873 shoichi@med.kurume-u.ac.jp Sub-Investigator: Sho-ichi Yamagishi, MD Nagaoka Red Cross Hospital Not yet recruiting Nagaoka, Niigata, Japan, 940-2085 Contact: Kyuzi Kamoi, MD +81-0258-28-3600 kkam-int@echogo.ne.jp Principal Investigator: Kyuzi Kamoi, MD Sub-Investigator: Sho-ichi Yamagishi, MD 收起 <<
NCT02683226	Polycystic Ovary Syndrome ... 展开 >> Insulin Resistance 收起 <<	Phase 4	Completed	-	Slovenia ... 展开 >> University Medical Center Ljubljana Ljubljana, Slovenia, 1000 收起 <<
NCT01632007	Diabetes Mellitus	Phase 3	Completed	-	Japan ... 展开 >> Akita-shi, Akita, Japan Matsudo-shi, Chiba, Japan Fukuoka-shi, Fukuoka, Japan Fukuyama-shi, Hiroshima, Japan Ishikari-shi, Hokkaido, Japan Nakagawa-gun, Hokkaido, Japan Sapporo-shi, Hokkaido, Japan Naka-shi, Ibaragi, Japan Sagamihara-shi, Kanagawa, Japan Kumamoto-shi, Kumamoto, Japan Kashiwara-shi, Osaka, Japan Osaka-shi, Osaka, Japan Suita-shi, Osaka, Japan Arakawa-ku, Tokyo, Japan Bunkyo-ku, Tokyo, Japan Chiyoda-ku, Tokyo, Japan Chuo-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Katsushika-ku, Tokyo, Japan Mitaka-shi, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Shunan-shi, Yamaguchi, Japan 收起 <<
NCT00755846	Diabetes Mellitus	Phase 2	Completed	-	-
NCT01686711	Diabetes Mellitus	Phase 4	Completed	-	Japan ... 展开 >> Hirosaki-shi, Aomori, Japan Kisaratsu-shi, Chiba, Japan Matsuyama-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Kitakyushu-shi, Fukuoka, Japan Kurume-shi, Fukuoka, Japan Fukuyama-shi, Hiroshima, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Koga-shi, Ibaraki, Japan Yokohama-shi, Kanagawa, Japan Kumamoto-shi, Kumamoto, Japan Miyazaki-shi, Miyazaki, Japan Suita-shi, Osaka, Japan Koshigaya-shi, Saitama, Japan Otsu-shi, Shiga, Japan Chiyoda-ku, Tokyo, Japan Chuo-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Meguro-ku, Tokyo, Japan Minato-ku, Tokyo, Japan Ohta-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toyama-shi, Toyama, Japan Shimonoseki-shi, Yamaguchi, Japan 收起 <<
NCT03231709	Type 2 Diabetes Mellitus	Phase 4	Completed	-	Japan ... 展开 >> OCROM Clinic Suita, Osaka, Japan ToCROM Clinic Shinjuku, Tokyo, Japan 收起 <<
NCT02823808	Diabetes	Phase 4	Recruiting	December 2021	Korea, Republic of ... 展开 >> Kyunghee University Medical Center Recruiting Seoul, Korea, Republic of Contact: Sang Youl Rhee 收起 <<
NCT00755846	-		Completed	-	-
NCT02426294	Type 2 Diabetes Mellitus	Phase 4	Unknown	May 2016	Korea, Republic of ... 展开 >> Pusan National University Hospital Recruiting Busan, Korea, Republic of, 602-739 Contact: Sang Soo Kim, MD., PhD. +82-51-240-7228 drsskim7@gmail.com Contact: Jong Ho Kim, MD. +82-51-240-7983 bedaya@hanmail.net 收起 <<
NCT02276274	Clinical Pharmacology	Phase 3	Completed	-	Japan ... 展开 >> Fukuoka-shi, Fukuoka, Japan 收起 <<
NCT01263470	-		Completed	-	-
NCT01075763	Alzheimer's Disease	Phase 2	Completed	-	Italy ... 展开 >> U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina Catania, CT, Italy, 95122 收起 <<
NCT01263470	Diabetes Mellitus, Type 2	Phase 2	Completed	-	Japan ... 展开 >> Okayama, Japan, 701-0192 收起 <<
NCT01263496	Type 2 Diabetes Mellitus	Phase 2	Completed	-	-
NCT00432276	Diabetes Mellitus	Phase 3	Completed	-	-
NCT02276274	-		Completed	-	-
NCT02763007	Diabetes Mellitus, Type 2	Phase 4	Recruiting	September 2020	Korea, Republic of ... 展开 >> Seoul St Mary's Hospital, The Catholic University of Korea Recruiting Seoul, Korea, Republic of, 137-701 Contact: YOON HEE CHOI, MD Principal Investigator: Kun-Ho Yoon, MD, PhD Sub-Investigator: Yoon-Hee Choi, MD, PhD Sub-Investigator: Eun-Young Lee, MD, PhD 收起 <<
NCT00432276	-		Completed	-	-
NCT00328627	Type 2 Diabetes Mellitus	Phase 3	Completed	-	-
NCT00395512	Diabetes Mellitus	Phase 3	Completed	-	-
NCT00286494	-		Completed	-	-
NCT01263496	-		Completed	-	-
NCT01964976	-		Completed	-	-
NCT00286494	Diabetes Mellitus	Phase 3	Completed	-	-
NCT00286442	Diabetes Mellitus	Phase 3	Completed	-	-
NCT02798172	Diabetes Mellitus, Type 2	Not Applicable	Completed	-	-
NCT01964976	-		Completed	-	Japan ... 展开 >> Tokyo, Japan 收起 <<
NCT01964950	-		Completed	-	Japan ... 展开 >> Tokyo, Japan 收起 <<
NCT00328627	-		Completed	-	-
NCT00395512	-		Completed	-	-
NCT00286442	-		Completed	-	-
NCT01964950	-		Completed	-	-
NCT01664624	Type 2 Diabetes	Phase 1	Completed	-	United States, California ... 展开 >> Chula Vista, California, United States United States, Florida Orlando, Florida, United States 收起 <<
NCT01664624	-		Completed	-	-
NCT02231021	Type 2 Diabetes Mellitus	Phase 4	Recruiting	November 2018	Korea, Republic of ... 展开 >> Seoul St Mary's Hospital, The Catholic University of Korea Recruiting Seoul, Korea, Republic of, 137-701 Principal Investigator: Kun-Ho Yoon, MD, PhD Sub-Investigator: Yoon-Hee Choi, MD, PhD Sub-Investigator: Hye-Kyung Yang, MD 收起 <<
NCT01263483	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT01263483	-		Completed	-	-
NCT01318135	-		Completed	-	-
NCT00655863	Diabetes Mellitus	Phase 3	Completed	-	Netherlands ... 展开 >> Amsterdam, Netherlands Sweden Gothenburg, Sweden 收起 <<
NCT01318135	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT00286429	Diabetes Mellitus	Phase 3	Completed	-	-
NCT01289119	Diabetes Mellitus, Type 2	Phase 3	Completed	-	-
NCT01289119	-		Completed	-	-
NCT00286468	Diabetes Mellitus	Phase 3	Completed	-	-
NCT01318109	-		Completed	-	-
NCT00286468	-		Completed	-	-
NCT01023581	Diabetes Mellitus, Type 2	Phase 3	Completed	-	-
NCT01318109	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT00286429	-		Completed	-	-
NCT00286455	-		Completed	-	-
NCT01023581	-		Completed	-	-
NCT01318083	-		Completed	-	-
NCT00286455	Diabetes Mellitus	Phase 3	Completed	-	-
NCT01318083	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT00655863	-		Completed	-	-
NCT01318070	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT01890122	Diabetes Mellitus	Phase 3	Completed	-	-
NCT01318070	-		Completed	-	-
NCT01890122	-		Completed	-	-
NCT01303055	Diabetes Mellitus, Type 2	Not Applicable	Unknown	December 2014	Japan ... 展开 >> Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University Recruiting Nagoya, Aichi, Japan, 464-8650 Contact: Takahiro Tosaki, MD, PhD +81-52-759-2111 nrd49075@nifty.com Principal Investigator: Takahiro Tosaki, MD, PhD Sub-Investigator: Keiko Naruse, MD, PhD Tosaki Clinic for Diabetes and Endocrinology Not yet recruiting Nagoya, Aichi, Japan, 468-0009 Contact: Takahiro Tosaki, MD, PhD nrd49075@nifty.com Principal Investigator: Takahiro Tosaki, MD, PhD Diabetes Clinic, Okazaki East Hospital Recruiting Okazaki, Aichi, Japan, 444-0008 Contact: Takahiro Tosaki, MD, PhD +81-564-22-6616 nrd49075@nifty.com Sub-Investigator: Chizuko Suzuki, MD, PhD Sub-Investigator: Maiko Mizutani, MD, PhD Principal Investigator: Takahiro Tosaki, MD, PhD Diabetes Center, Yokkaichi Social Insurance Hospital Recruiting Yokkaichi, Mie, Japan, 510-0016 Contact: Takahiro Tosaki, MD, PhD +81-59-331-2000 nrd49075@nifty.com Sub-Investigator: Miho Miyoshi, MD Sub-Investigator: Tomoki Majima, MD Principal Investigator: Takahiro Tosaki, MD, PhD 收起 <<
NCT02068443	Type 2 Diabetes Mellitus	Phase 3	Completed	-	Japan ... 展开 >> Nagoya-shi, Aichi, Japan Chiba-shi, Chiba, Japan Fukuoka-shi, Fukuoka, Japan Kitakyushu-shi, Fukuoka, Japan Kurume-shi, Fukuoka, Japan Aki-gun, Hiroshima, Japan Hiroshima-shi, Hiroshima, Japan Koga-shi, Ibaraki, Japan Mito-shi, Ibaraki, Japan Tushiura-shi, Ibaraki, Japan Ushiku-shi, Ibaraki, Japan Kanazawa-shi, Ishikawa, Japan Takamatsu-chi, Kagawa, Japan Sendai-shi, Miyagi, Japan Ohita-shi, Ohita, Japan Okinawa-shi, Okinawa, Japan Shimajiri-gun, Okinawa, Japan Kashiwara-shi, Osaka, Japan Osaka-shi, Osaka, Japan Hiki-gun, Saitama, Japan Oyama-shi, Tochigi, Japan Shimotsuke-shi, Tochigi, Japan Koutoh-ku, Tokyo, Japan Meguro-ku, Tokyo, Japan Sagae-shi, Yamagata, Japan Yamagata-shi, Yamagata, Japan Yamaguchi-shi, Yamaguchi, Japan 收起 <<
NCT00856284	-		Completed	-	-
NCT01263509	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT00707993	-		Completed	-	-
NCT01521962	Diabetes Mellitus	Phase 3	Completed	-	Japan ... 展开 >> Aomori-shi, Aomori, Japan Hirosaki-shi, Aomori, Japan Kashiwa-shi, Chiba, Japan Kisarazu-shi, Chiba, Japan Kitakyushu-shi, Fukuoka, Japan Aki-gun, Hiroshima, Japan Fukuyama-shi, Hiroshima, Japan Nishinomiya-shi, Hyogo, Japan Koga-shi, Ibaraki, Japan Ushiku-shi, Ibaraki, Japan Kahoku-gun, Ishikawa, Japan Hanamaki-shi, Iwate, Japan Morioka-shi, Iwate, Japan Kagoshima-shi, Kagoshima, Japan Satsuma-sendai-shi, Kagoshima, Japan Kumamoto-shi, Kumamoto, Japan Minamata-shi, Kumamoto, Japan Miyazaki-shi, Miyazaki, Japan Nigata-shi, Nigata, Japan Hirakata-shi, Osaka, Japan Osaka-sayama-shi, Osaka, Japan Osaka-shi, Osaka, Japan Takatsuki-shi, Osaka, Japan Yao-shi, Osaka, Japan Kuki-shi, Saitama, Japan Otsu-shi, Shiga, Japan Hamamatsu-shi, Shizuoka, Japan Shizuoka-shi, Shizuoka, Japan Shimotsuke-shi, Tochigi, Japan Shinagawa-ku, Tokyo, Japan Toyama-shi, Toyama, Japan Sagae-shi, Yamagata, Japan Yamagata-shi, Yamagata, Japan 收起 <<
NCT01318122	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT01263509	-		Completed	-	-
NCT02068443	-		Completed	-	-
NCT02508168	Healthy Volunteers	Phase 1	Completed	-	-
NCT00707993	Diabetes Mellitus	Phase 3	Completed	-	-
NCT00306384	Diabetes Mellitus	Phase 3	Completed	-	-
NCT00856284	Type 2 Diabetes Mellitus	Phase 3	Completed	-	-
NCT02771093	Type 2 Diabetes Mellitus	Phase 4	Completed	-	Japan ... 展开 >> Naka-city, Ibaragi, Japan 收起 <<
NCT00306384	-		Completed	-	-
NCT01318122	-		Completed	-	-
NCT01391663	-		Completed	-	-
NCT02771093	-		Completed	-	-
NCT01964963	-		Completed	-	Japan ... 展开 >> Tokyo, Japan 收起 <<
NCT00968708	Diabetes Mellitus, Type 2 ... 展开 >> Acute Coronary Syndrome 收起 <<	Phase 3	Completed	-	-
NCT01945242	-		Completed	-	-
NCT01391663	Pharmacokinetics and Pharmacod... 展开 >>ynamics 收起 <<	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Seoul, Korea, Republic of 收起 <<
NCT01456130	-		Completed	-	-
NCT00957268	Diabetes Mellitus, Type 2	Phase 1	Completed	-	United States, Florida ... 展开 >> Miami, Florida, United States Pineallas Park, Florida, United States United States, Kentucky Louisville, Kentucky, United States United States, North Carolina Durham, North Carolina, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, Tennessee Memphis, Tennessee, United States United States, Texas San Antonio, Texas, United States 收起 <<
NCT01945242	-		Completed	-	-
NCT01456130	Diabetes Mellitus	Phase 3	Completed	-	Japan ... 展开 >> Nagoya-shi, Aichi, Japan Fukuoka-shi, Fukuoka, Japan Kurume-shi, Fukuoka, Japan Sapporo-shi, Hokkaido, Japan Kobe-shi, Hyogo, Japan Kagoshima-shi, Kagoshima, Japan Kumamoto-shi, Kumamoto, Japan Osaki-shi, Miyagi, Japan Minou-shi, Osaka, Japan Osaka-shi, Osaka, Japan Kamio-shi, Saitama, Japan Koshigaya-shi, Saitama, Japan Adachi-ku, Tokyo, Japan Chuo-ku, Tokyo, Japan 收起 <<
NCT03501277	Healthy Volunteers	Phase 1	Completed	-	Russian Federation ... 展开 >> Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways Yaroslavl, Russian Federation, 150047 收起 <<
NCT00968708	-		Completed	-	-
NCT01945216	-		Completed	-	Japan ... 展开 >> Osaka, Japan 收起 <<
NCT00957268	-		Completed	-	-
NCT01990300	-		Completed	-	-
NCT02989649	-		Terminated(Business Decision; ... 展开 >>No Safety Or Efficacy Concerns) 收起 <<	-	China, Beijing ... 展开 >> Beijing, Beijing, China China, Hubei Wuhan, Hubei, China China, Liaoning Dalian, Liaoning, China Shenyang, Liaoning, China China, Shandong Jinan, Shandong, China Qingdao, Shandong, China Tai'an, Shandong, China Taian, Shandong, China China, Tianjin Tianjin, Tianjin, China Hong Kong Sai Ying Pun, Hong Kong Sha Tin, Hong Kong 收起 <<
NCT01945216	-		Completed	-	-
NCT03499704	Diabetes Mellitus, Type 2	Phase 4	Not yet recruiting	December 31, 2020	-
NCT02756832	-		Completed	-	-
NCT02221284	-		Completed	-	Japan ... 展开 >> Osaka, Japan Tokyo, Japan 收起 <<
NCT03042325	Diabetes Mellitus, Type 2	Phase 4	Withdrawn(Business decision, n... 展开 >>o safety or efficacy concerns) 收起 <<	January 15, 2018	-
NCT02856113	Diabetes Mellitus, Type 2	Phase 3	Recruiting	June 11, 2021	-
NCT03555565	-		Active, not recruiting	October 31, 2019	Japan ... 展开 >> Takeda Selected Site Tokyo, Japan 收起 <<

阿格列汀 /Alogliptin {[allProObj[0].p_purity_real_show]}

Alogliptin 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Alogliptin 质控信息

Alogliptin 生物活性

Alogliptin 临床研究

Alogliptin 参考文献

Alogliptin 实验方案

Alogliptin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

阿格列汀 /Alogliptin {[allProObj[0].p_purity_real_show]}

Alogliptin 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Alogliptin 质控信息

Alogliptin 生物活性

Alogliptin 临床研究

Alogliptin 参考文献

Alogliptin 实验方案

Alogliptin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Alogliptin 纯度/质量文件产品仅供科研